Description

Product Description

Riminkefon is a synthetic compound classified as a kappa opioid receptor (KOR) agonist, developed for use in laboratory and preclinical research settings. KORs are a distinct subclass of opioid receptors, alongside mu (MOR) and delta (DOR), and are widely distributed in the central nervous system and peripheral tissues. Unlike mu-opioid agonists, which are traditionally associated with analgesia but also addiction and respiratory depression, KOR agonists such as Riminkefon offer an alternative pharmacological profile with unique research implications.

One of the major scientific interests surrounding Riminkefon lies in its potential to model non-addictive analgesic pathways. Research suggests that selective KOR activation produces significant analgesia without reinforcing reward pathways, making it an essential reference tool for the development of novel pain therapeutics. Additionally, Riminkefon provides an opportunity to investigate stress response modulation, as KORs are implicated in corticotropin-releasing factor (CRF) signaling and hypothalamic-pituitary-adrenal (HPA) axis regulation.

In psychiatric research, Riminkefon is highly valuable for studies in depression, anxiety, and addiction biology. Preclinical models have demonstrated that KOR activation may influence mood regulation, dysphoria, and stress coping mechanisms, offering a dual framework for both therapeutic exploration and side-effect profiling. Its activity profile makes it a key compound for understanding the balance between therapeutic efficacy and adverse effects in translational neuroscience research.

From a pharmacological perspective, Riminkefon is characterized by high receptor selectivity toward the KOR, minimizing unwanted off-target binding at MOR or DOR receptors. This allows for clearer interpretation of receptor-mediated signaling pathways. Researchers have reported reproducible activity in both in vitro receptor-binding assays and in vivo rodent models, making it suitable for cross-platform investigations.

The compound’s GMP-grade production ensures high chemical purity and lot-to-lot consistency. Each batch undergoes rigorous quality control to validate structural identity, purity, and stability, thereby ensuring experimental reproducibility. The lyophilized form provides extended shelf stability, making it suitable for long-term storage and repeated use in controlled experiments.

Overall, Riminkefon stands out as a specialized research compound in opioid pharmacology, bridging neurobiology, pain research, and psychiatric investigation. Its defined mechanism of action, high receptor selectivity, and robust GMP-grade quality make it a critical tool for researchers worldwide.

Product Specifications

Mechanism of Action & Research Applications

Riminkefon acts primarily through selective activation of the kappa opioid receptor (KOR), a G-protein coupled receptor (GPCR) widely expressed in the brain, spinal cord, and peripheral nervous system. Upon agonist binding, the KOR undergoes conformational change, leading to downstream inhibition of adenylyl cyclase and modulation of ion channel activity. This produces a net reduction in neuronal excitability, contributing to analgesic and anxiolytic effects in experimental models.

Key Mechanistic Pathways:

• Inhibition of Adenylyl Cyclase ? Decreased cyclic AMP (cAMP) levels, reducing excitatory neurotransmitter release.

• Potassium Channel Activation ? Hyperpolarization of neurons, decreasing excitability.

• Calcium Channel Modulation ? Reduced presynaptic calcium influx, lowering neurotransmitter release.

• Interaction with Stress Pathways ? Crosstalk with CRF and HPA axis signaling, influencing mood and stress resilience.

Research Applications:

1. Pain Research – Riminkefon provides a model for studying non-addictive analgesia, enabling comparison with MOR agonists.

2. Addiction Studies – Useful for exploring KOR’s role in drug withdrawal, craving, and relapse prevention.

3. Mood Disorders – Enables mechanistic studies in depression, dysphoria, and anxiety, focusing on KOR-related circuits.

4. Stress Modulation – Investigates how KOR activation influences stress coping and resilience.

5. Neurobiology – Serves as a probe for opioid receptor signaling, receptor desensitization, and GPCR pharmacology.

6. Combination Therapy Models – Explored alongside antidepressants, MOR antagonists, or neuromodulators.

7. Translational Research – Supports preclinical insights into KOR agonists as therapeutic candidates for pain and psychiatric disorders.

   

Side Effects (For Reference in Research Models)

Preclinical data indicate that Riminkefon, like other KOR agonists, may present the following experimental observations:

• Dysphoria and Anhedonia – Reported in animal models as part of stress-related behavioral outcomes.

• Sedation – High doses may lead to reduced locomotor activity.

• Diuresis – KOR agonists are associated with increased urine output in some models.

• Cognitive Effects – Short-term alterations in memory and attention may be observed.

• Gastrointestinal Responses – Possible changes in gut motility at high concentrations.

• Cardiovascular Responses – Minor transient changes in heart rate or blood pressure.

• Tolerance and Desensitization – Chronic exposure may induce receptor downregulation.

• Model-Specific Variability – Effects depend on species, dose, and administration route.

?? These findings are strictly for laboratory reference. Riminkefon is not approved for human or veterinary use.

Disclaimer

For laboratory research use only. Not for human or veterinary use.

Keywords

• Riminkefon

• Riminkefon CAS 2168572-99-2

• Kappa opioid receptor agonist

• Selective KOR agonist research compound

• GMP-grade KOR agonist

• Laboratory use opioid receptor tool

• Riminkefon wholesale supplier

• Pain research KOR agonist

• Stress and mood regulation compound

• Preclinical opioid receptor pharmacology